Advances in the treatment of fragile X syndrome - Wikidata - awgldk - TriplyDB

Advances in the treatment of fragile X syndrome

Advances in the treatment of fragile X syndrome

http://www.wikidata.org/entity/Q24632814

about

L-acetylcarnitine for treating fragile X syndrome L-acetylcarnitine for fragile X syndrome Folic acid for fragile X syndrome Folic acid for fragile X syndrome Importance of Shank3 protein in regulating metabotropic glutamate receptor 5 (mGluR5) expression and signaling at synapses One world, one woman What can we learn about autism from studying fragile X syndrome?Emerging pharmacotherapies for neurodevelopmental disorders Group 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and disease Genetics of autistic disorders: review and clinical implications Fragile x syndrome Systematic review of pharmacological treatments in fragile X syndrome RNA Secondary Structure Modulates FMRP's Bi-Functional Role in the MicroRNA Pathway Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder Emerging pharmacologic treatment options for fragile X syndrome Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments Fragile X syndrome as a rare disease in China - Therapeutic challenges and opportunities Fragile X syndrome and targeted treatment trials.Fragile X syndrome Dendritic spine dysgenesis in autism related disorders Unstable mutations in the FMR1 gene and the phenotypes The contribution of inhibitory interneurons to circuit dysfunction in Fragile X Syndrome Fragile X mental retardation protein regulates olfactory sensitivity but not odorant discrimination Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Fragile X syndrome: A review of clinical management Study of the Genetic Etiology of Primary Ovarian Insufficiency: FMR1 Gene The neurobiology of the Prader-Willi phenotype of fragile X syndrome MOV10 and FMRP regulate AGO2 association with microRNA recognition elements Reduced gamma oscillations in a mouse model of intellectual disability: a role for impaired repetitive neurotransmission?Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.Exploring the zebra finch Taeniopygia guttata as a novel animal model for the speech-language deficit of fragile X syndrome Behavioural phenotyping assays for mouse models of autism Role of Genetics in the Etiology of Autistic Spectrum Disorder: Towards a Hierarchical Diagnostic Strategy.Degraded speech sound processing in a rat model of fragile X syndrome Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model.Fragile X: leading the way for targeted treatments in autism.Cardiovascular and behavioral response to auditory stimuli in boys with fragile X syndrome.Auditory processing in fragile x syndrome.Inhibition of spontaneous recovery of fear by mGluR5 after prolonged extinction training The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

P2860

Q24187914-5702CDE9-4E3F-44A7-B4BB-987466211018 Q24201787-54062280-B3F2-410F-AD7E-6FA8043AFB12 Q24234634-8231A7FF-171E-49D7-A079-7A2281FC98C9 Q24236213-06BBE8A7-29B7-45AF-924B-6B7B46CB467B Q24317227-79FA029A-8571-46CD-BF7A-39DCF4999418 Q24612879-72EFDA66-0A62-4B2D-A51E-61B6FAF825B3 Q24613049-E4DD2F84-2DE0-44B3-A799-2D7C9CAE4C08 Q24619170-0EDE4C05-9DEE-4F06-8C55-D4C12C5D74B4 Q24620534-645A0009-ECF8-4CEF-A914-B3741BC0FCCA Q24627520-8F0DBB59-101D-4A1F-AAA7-1E742829B53B Q24633000-F3C36519-63B3-426C-90F2-315C39008852 Q24647106-945AC87A-3B2F-4619-91A7-715B88CB6B99 Q26747489-03FBDFC9-9198-4A29-B84D-58F4DE00E339 Q26781265-F5389635-C9E2-48F0-8884-87B773D87F05 Q26829152-7CC9C8C9-8189-4216-A826-679C3265DE7F Q26850307-ED1E2B3F-6EF2-41E2-807A-0C5DD1635FC2 Q26863615-5004E8DB-AC99-4861-BEEB-0AE3AEEE428E Q26865162-25AC0570-1A86-4075-9C3D-2A6E2057DFC4 Q26995168-C3DA3755-5A08-4116-BAB2-8D4FBC34745D Q26995242-4495209A-D1B9-4097-AA4C-3DD298844C29 Q26996649-6E64FEC6-32FB-4C1E-B6ED-5F0A9510D032 Q26998540-A83E26C0-F1D2-4DFF-9A1A-17DFE26EA8E8 Q27302324-A213B81E-5AFA-4CCE-84E6-0461AD480EF2 Q27337360-2658A8C7-CD8D-4D3E-9D85-39E7063E14C5 Q28076950-26DE5389-095F-4A76-9A87-5F49DA48DD63 Q28077015-5CF1975D-9BCE-4D57-8E9F-3A4B5AAB870F Q28078294-CC11D27E-ED49-4B66-85A7-0EE3B0EB222E Q28117661-1D49990B-2492-46DC-8A2B-0606080B94D2 Q28538532-6D87060B-9B24-4E1B-8DD3-9400CE20D16F Q28593254-93418094-EC46-43E6-9BB0-603EE6918140 Q28649423-81B540C4-CAFC-4D9D-874C-40F9E1B69381 Q29618414-62065A4A-B4B2-4DEC-80D8-466AD0762618 Q30235312-F5BE5057-E03C-4993-A423-ADAB2D82AEBB Q30411291-FEE0A399-7E61-453E-A1D0-F9C002D6A950 Q30411531-68AB7B88-3671-466E-8828-842F0DE84245 Q30435321-49A1B389-EEDD-44F3-A15D-A6EC966E3F7E Q30440893-7ABB01E5-B6B5-4D78-A694-DECD1CF7CDB2 Q30442883-611ACDA9-8E76-4321-BAAE-BA9F79D9A054 Q30455712-0FDC09D3-1696-4C25-ACD4-6D930D9FEAFF Q30461456-BBA9C995-B941-4EC8-A743-45F21390E814

P2860

Advances in the treatment of fragile X syndrome

http://www.wikidata.org/entity/Q24632814

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Advances in the treatment of fragile X syndrome

@ast

Advances in the treatment of fragile X syndrome

@en

Advances in the treatment of fragile X syndrome

@nl

type

label

Advances in the treatment of fragile X syndrome

@ast

Advances in the treatment of fragile X syndrome

@en

Advances in the treatment of fragile X syndrome

@nl

prefLabel

Advances in the treatment of fragile X syndrome

@ast

Advances in the treatment of fragile X syndrome

@en

Advances in the treatment of fragile X syndrome

@nl

P1433

Q24632814-01C9FA32-7C4A-4593-A0B8-9459251BE186

P1476

Q24632814-D07B0990-32CC-40DE-B505-A2CF0F495B73

P2093

Q24632814-064D7A6C-45B7-41DA-9BA7-D8B0624E5003

Q24632814-0D3EC86C-DAB7-46EA-A8F7-F329DB5DC557

Q24632814-1B09B0A1-9262-4D4A-A13C-033041C90751

Q24632814-3771F69F-B89C-4285-84DB-5235D2AED891

Q24632814-4ACE9C4B-903A-4098-A73A-BB9956B49C55

Q24632814-736E7BD1-832F-4C9B-8D1E-A8AC835390BF

Q24632814-7BFEB10F-F960-4992-8804-1C16448EA2FE

Q24632814-853ACD92-4D83-41C0-86C5-B5CCA7840517

Q24632814-8C59AFE7-AC9C-4900-A9E0-EA8A806E8600

Q24632814-95F10ADA-DECC-40E2-98EF-EA0EFC817117

P2860

Q24632814-001E7935-21DD-4731-884D-5630E3DD839B

Q24632814-03154B3C-553C-47EA-A536-D71F8572F760

Q24632814-03EAB4EF-203E-48BC-8033-322608EDF4CD

Q24632814-05CF469C-6981-4BF4-B257-2DE8A58E67DA

Q24632814-09B91487-BDF5-4150-9C08-87C7D73793DE

Q24632814-0AD33E43-50FF-4E82-A9C7-D6103A680B6A

Q24632814-0D3977DF-BF9E-4FA1-9791-3D84CF399834

Q24632814-10CF4C8F-6AB5-4D86-BB14-4333B108CB03

Q24632814-124BA73F-BF07-4991-B43B-E4B4D449FE90

Q24632814-12FD216C-7BAB-4D89-924E-7D2B0E66C1DB

P304

Q24632814-C79CD3E1-5A2C-48F7-A025-CF1B07822324

P31

Q24632814-934B8E4E-E78E-4A44-9892-30662C84CE34

P3181

Q24632814-AD78A208-FEE2-4427-AB78-002E17558E55

P356

Q24632814-08A5EFC4-CF30-494C-87D0-26B267EFD5AC

P407

Q24632814-2FDE011D-DF7D-4E5B-9521-E9F14D52529B

P433

Q24632814-AA596003-31BA-47E6-8310-A9613262CFE4

P478

Q24632814-FC4DEB9C-F447-4FB4-81A3-EF90A4E91036

P577

Q24632814-5FE10D78-9A52-4CC8-8D47-7EB57B3F7421

P5875

Q24632814-BE1E4CC4-316F-446D-AA88-88220BF10DCF

P698

Q24632814-433D2FF0-E725-4ED2-B36F-042ACDCF2155

P932

Q24632814-FC7267BF-030F-49B8-9124-02861B11DE68

P3181

P356

P1433

P1476

Advances in the treatment of fragile X syndrome

@en

P2093

Ave Lachiewicz

http://www.w3.org/2001/XMLSchema#string

Carol Delahunty

http://www.w3.org/2001/XMLSchema#string

David Hessl

http://www.w3.org/2001/XMLSchema#string

Elizabeth Berry-Kravis

http://www.w3.org/2001/XMLSchema#string

Jeannie Visootsak

http://www.w3.org/2001/XMLSchema#string

Jonathan Picker

http://www.w3.org/2001/XMLSchema#string

Louise Gane

http://www.w3.org/2001/XMLSchema#string

Michael Tranfaglia

http://www.w3.org/2001/XMLSchema#string

Michele Y Ono

http://www.w3.org/2001/XMLSchema#string

Nicole Tartaglia

http://www.w3.org/2001/XMLSchema#string

P2860

Correction of fragile X syndrome in mice.

Genome-wide expression profiling of lymphoblastoid cell lines distinguishes different forms of autism and reveals shared pathways

Altered synaptic plasticity in a mouse model of fragile X mental retardation

Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons

The fragile-X premutation: a maturing perspective.

Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X

Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist

Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population

From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome

Pharmacologic treatment of autism and related disorders

P304

378-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

579337

http://www.w3.org/2001/XMLSchema#string

P356

10.1542/PEDS.2008-0317

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23715107

http://www.w3.org/2001/XMLSchema#string

P698

19117905

http://www.w3.org/2001/XMLSchema#string

P932

2888470

http://www.w3.org/2001/XMLSchema#string